Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Operating Expenses: 2019-2024

Historic Other Operating Expenses for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $3.9 million.

  • BridgeBio Pharma's Other Operating Expenses rose 997.49% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 524.54%. This contributed to the annual value of $3.9 million for FY2024, which is 58.54% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Other Operating Expenses of $3.9 million as of FY2024, which was up 58.54% from $2.4 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Other Operating Expenses peaked at $3.9 million during FY2024, and registered a low of $2.4 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Other Operating Expenses value was $3.4 million (recorded in 2022), while the average stood at $3.3 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first dropped by 28.77% in 2023, then spiked by 58.54% in 2024.
  • Over the past 4 years, BridgeBio Pharma's Other Operating Expenses (Yearly) stood at $3.1 million in 2021, then grew by 10.28% to $3.4 million in 2022, then dropped by 28.77% to $2.4 million in 2023, then spiked by 58.54% to $3.9 million in 2024.